Your location:Home page > Program
Search:
Symposium:
  • All
  • State-of-the-art Session
  • Postgraduate Course
  • Concurrent Session
  • Oral Presentation
  • Young Investigator Forum
  • Special Session - Pediatrics Issue
  • Satellite Symposium
Date (UTC+8):
  • All
  • 2022-09-16 [Fri]
  • 2022-09-17 [Sat]
  • 2022-09-18 [Sun]
Hall:
  • All
  • Meeting Room 1
  • Meeting Room 2
  • Meeting Room 3

2022-09-16 Fri

Meeting Room 1 (UTC+8) 2022-09-16 Local Time

08:30-10:00 (UTC+8) 08:30-10:00 Local Time | State-of-the-art Session 1 [State-of-the-art Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
08:30-09:00 08:30-09:00

Reflections on the prevention and control of COVID-19 and future global pandemics

George Fu Gao Institute of Microbiology, Chinese Academy of Sciences
09:00-09:30 09:00-09:30

Clinical and immunological features of COVID-19 : Implications for management

Qin NING Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
09:30-11:00 09:30-11:00

Severe acute non-A-E hepatitis in Children in 2021-2022 and managing a global response

Philippa J. EASTERBROOK WHO Headquarters in Geneva
10:00-11:30 (UTC+8) 10:00-11:30 Local Time | Postgraduate Course 1 - COVID 19 [Postgraduate Course]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
10:00-10:20 10:00-10:20

Global COVID-19 epidemic trend and the construction of China's public health system

Hongzhou LU The Third People's Hospital of Shenzhen
10:20-10:40 10:20-10:40

Safety and immunogenicity of COVID-19 vaccination in patients with liver diseases

Wenhong ZHANG Huashan Hospital Fudan University
10:40-11:00 10:40-11:00

The mechanism underlying extrapulmonary complications of the coronavirus disease 2019

Di WU Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
11:00-11:20 11:00-11:20

MRI evaluation of COVID-19 related brain injury MRI evaluation of COVID-19 related brain injury

Yuanyuan Qin Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
11:20-11:30 11:20-11:30

Panel Discussion

11:30-11:45 (UTC+8) 11:30-11:45 Local Time | Break
11:45-13:15 (UTC+8) 11:45-13:15 Local Time | Oral Presentation 1 [Oral Presentation]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
11:45-11:57 11:45-11:57

Clinical characteristics and prognosis of concomitant autoimmune hepatitis and nonalcoholic fatty liver disease

Min ZHU The Second Affiliated Hospital of Chongqing Medical University
11:57-12:09 11:57-12:09

Human umbilical cord blood mononuclear cells ameliorate CCl4-induced acute liver injury in mice via inhibiting inflammatory responses and up-regulating peripheral interleukin-22

Jinming ZHANG Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
12:09-12:21 12:09-12:21

CMTM4 promotes the proliferation and metastasis of hepatocellular carcinoma through the regulation of AKT and PD-L1

Ziyu Chu Fu yang Second People's Hospital
12:21-12:33 12:21-12:33

Soluble Fibrinogen-Like Protein 2 Promotes the Progression of Hepatocellular Carcinoma by Inducing the Expression of Immune Checkpoints

Meiwen HAN Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
12:45-12:57 12:45-12:57

Small extracellular vesicles derived from induced pluripotent stem cells to alleviate lipopolysaccharide /D-galactosamine induced acute liver failure

Ying LUO Tianjin third central hospital
12:57-13:09 12:57-13:09

Significant serum proteinic and metabolic alterations in hepatitis B cirrhosis patients treated with umbilical cord mesenchymal stem cells

Ying Shi University of Electronic Science and Technology of China
13:15-13:30 (UTC+8) 13:15-13:30 Local Time | Satellite Symposium [Satellite Symposium]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:15-13:30 13:15-13:30

Clinical value of highly sensitive detection in CHB LLV patients

Tao CHEN Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
13:45-15:15 (UTC+8) 13:45-15:15 Local Time | Postgraduate Course 2 - Basic and Clinical Research in Viral Hepatitis [Postgraduate Course]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:45-14:05 13:45-14:05

Novel biomarkers for the management of chronic hepatitis B

Yasuhito Tanaka Department of Orthopedic Surgery, Nara Medical University
14:05-14:25 14:05-14:25

Definition of HBV cure and treatment endpoint

George Lau Humanity & Health Medical Group/The 5th Medical Centre of Chinese PLA General Hospital
14:25-14:45 14:25-14:45

Basic biology of HBV: glance over cccDNA transcription

Wenhui LI National Institute of Biological Sciences, Beijing
14:45-15:05 14:45-15:05

Quantitative anti-HBc but not HBcrAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NAs-suppressed chronic hepatitis B patients

Junliang FU The Fifth Medical Center of Chinese PLA General Hospital
15:05-15:15 15:05-15:15

Panel Discussion

15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
15:30-17:00 (UTC+8) 15:30-17:00 Local Time | Oral Presentation 2 [Oral Presentation]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
15:30-15:42 15:30-15:42

24-week combination treatment of TLR7 agonist TQ-A3334 and PD-L1 inhibitor TQ-B2450 enhanced HBsAg reduction in NAs-suppressed CHB patients: a preliminary analysis of a phase II study (OCEANcure05)

Ting Wu Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
15:42-15:54 15:42-15:54

Immunogenicity of Inactivated COVID-19 Vaccines in Chronic Hepatitis B Patients with Antiviral Therapy

Wenxin WANG Peking University 302 Clinical Medical School
15:54-16:06 15:54-16:06

Lipid nanoparticle-mediated delivery of mRNA vaccine for IL-21 achieves clearance of hepatitis B virus (HBV) persistence in mouse models

Shenyan ZHANG Huashan hospital
16:06-16:18 16:06-16:18

Subcutaneous PD-L1 Antibody ASC22 (Envafolimab) plus Nucleos(t)ide Analogs Achieved Functional Cure of Chronic Hepatitis B in 42.9% of Patients with HBsAg ≤100 IU/mL: Interim Results from a Phase IIb Clinical Trial

Jiandan QIAN Peking university first hospital
16:18-16:30 16:18-16:30

Clinical evaluation of metagenomic next-generation sequencing method for the diagnosis of suspected ascitic infection in patients with liver cirrhosis in a clinical laboratory

Haoxin WU Capital medical university. Beijing youan hospital
16:30-16:42 16:30-16:42

Metabolic Factors and Steatosis Increase the Risk of Adverse Outcomes in Treatment-Naïve Chronic Hepatitis B Patients with Normal Alanine Aminotransferase

Yuting DIAO Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
16:42-16:54 16:42-16:54

High rates of HBV functional cure among HIV/HBV coinfected Chinese adults on antiretroviral therapy

Huan XIA Tianjin Second People's Hospital
17:00-18:30 (UTC+8) 17:00-18:30 Local Time | Postgraduate Course 3 - Liver Failure [Postgraduate Course]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:00-17:20 17:00-17:20

Prognosis era 2.0 for HBV-ACLF

Jun LI The First Affiliated Hospital, College of Medicine, Zhejiang University
17:20-17:40 17:20-17:40

Hepatic encephalopathy

Rajiv JALAN Institute for Liver and Digestive Health, UCL Medical School, London
17:40-18:00 17:40-18:00

Management of acute hepatic failure

Teerha PIRATVISUTH NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital
18:00-18:20 18:00-18:20

Management of end-stage liver disease complicated with infections

Tao CHEN Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
18:20-18:30 18:20-18:30

Panel Discussion

Meeting Room 2 (UTC+8) 2022-09-16 Local Time

13:15-15:15 (UTC+8) 13:15-15:15 Local Time | Young Investigator Froum 1 [Young Investigator Forum]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:15-13:35 13:15-13:35

Myeloid cells in alcohol related liver injury

Hua WANG Department of Oncology, the First Affiliated Hospital of Anhui Medical University
13:35-13:55 13:35-13:55

Research progress of non coding RNA in reversing liver fibrosis

Tianxin XIANG The First Affiliated Hospital of Nanchang University
13:55-14:15 13:55-14:15

Acute-on-chronic liver failure (ACLF) and regeneration

Xiaogang XIANG Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University
14:15-14:35 14:15-14:35

Immune-pathological mechanisms and potential therapies of liver diseases

Li Tang Academy of military medicine
14:35-14:55 14:35-14:55

Methylation biomarkers in acute-on-chronic hepatitis B liver failure

Yuchen FAN Department of Hepatology, Qilu Hospital of Shandong University
15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
15:30-17:30 (UTC+8) 15:30-17:30 Local Time | Young Investigator Froum 2 [Young Investigator Forum]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
15:30-17:00 15:30-17:00

Type-specific functions and related mechanisms of IFN-α against Hepatitis B Virus

Jieliang CHEN Shanghai Medical College of Fudan University
15:50-16:10 15:50-16:10

Plerixafor and resatorvid inhibit hepatitis B virus in vitro by upregulating EFTUD2

Chuanlong Zhu
16:10-16:30 16:10-16:30

Sofosbuvir-based therapy for late pregnant women and infant with severe chronic hepatitis C

Qinglei Zeng The First Affiliated Hospital of Xi'an Jiaotong University
16:30-16:50 16:30-16:50

Liver failure due to HBV reactivation

Yu Shi The First Affiliated Hospital Zhejang University
16:50-17:10 16:50-17:10

Liver failure:what we are doing and what we can do?

Liang PENG The Third Affiliated Hospital of Sun Yat sen Universit
17:10-17:30 17:10-17:30

Antiviral therapy in EBV infection

Jinghang XU Peking University First Hospital
17:30-19:30 (UTC+8) 17:30-19:30 Local Time | Special Session:Critical Care in Hepatology: Pediatrics Issue [Special Session - Pediatrics Issue]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:30-17:50 17:30-17:50

Explore the new etiology of childhood inherited cholestasis

Jianshe WANG Affiliated pediatric hospital of Fudan University
17:50-18:10 17:50-18:10

Landscape of Pediatric Liver Transplantation in Mainland China

Feng XUE Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University
18:10-18:30 18:10-18:30

How to diagnose primary immunodeficiency disease earlier?

Gang Liu Beijing Children's Hospital, Capital Medical University, National Center for Children's Health
18:30-18:50 18:30-18:50

Plasma exchange and pediatric acute liver failure

Quan WANG Beijing Children's Hospital
18:50-19:10 18:50-19:10

Management of children after liver transplantation

Zhengzheng Zhang Children’ Hospital of Fudan University
19:10-19:30 19:10-19:30

Sepsis induced liver injury

Hong REN Shanghai Children's Medical Center affiliated to Medical College of Shanghai Jiaotong University

2022-09-17 Sat

Meeting Room 1 (UTC+8) 2022-09-17 Local Time

08:00-09:30 (UTC+8) 08:00-09:30 Local Time | State-of-the-art Session 2 [State-of-the-art Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
08:00-08:30 08:00-08:30

Hepatology in Asia: 50 years and the future

Masao OMATA Yamanashi Central and Kita Hospitals, University of Tokyo
08:30-09:00 08:30-09:00

Update on IgG4-related cholangitis (IRC)

Jidong Jia Beijing Friendship Hospital Capital Medical University
09:00-09:30 09:00-09:30

CCIFLDI meets APASL: A history of first golden ten years

Qin NING Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
09:30-10:00 (UTC+8) 09:30-10:00 Local Time | Opening Ceremony
10:00-11:30 (UTC+8) 10:00-11:30 Local Time | Concurrent Session 1 - Management of Viral Hepatitis I [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
10:00-10:20 10:00-10:20

How to achieve WHO goal of HBV control?

Jia-Horng Kao National Taiwan University Hospital
10:20-10:40 10:20-10:40

Clinical utility of new viral biomarkers for CHB

Henry L.Y. Chan The Chinese University of Hong Kong
10:40-11:00 10:40-11:00

Stopping rules of NA therapy

Di WU Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
11:00-11:20 11:00-11:20

Severe HBV flare with acute-on-chronic liver failure

Man-Fung YUEN The University of Hong Kong
11:20-11:30 11:20-11:30

Panel Discussion

11:30-11:45 (UTC+8) 11:30-11:45 Local Time | Break
11:45-13:15 (UTC+8) 11:45-13:15 Local Time | Oral Presentation 3 [Oral Presentation]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
11:45-11:57 11:45-11:57

Difference between type 2 gastroesophageal varices and isolated fundic varices in clinical profiles and portosystemic collaterals

Yuhu Song Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
11:57-12:09 11:57-12:09

A low albumin to globulin ratio is a prognostic marker for bacterial infection in alcohol-related liver cirrhosis: a retrospective study

Furong SUN The First Hospital of China Medical University
12:09-12:21 12:09-12:21

Clinical evaluation of bacterial DNA using an improved droplet digital PCR for the diagnosis of spontaneous bacterial peritonitis

Haoxin WU Capital medical university. Beijing youan hospital
12:21-12:33 12:21-12:33

Research on Factors Linked with Occurrence of Minimal/Covert Hepatic Encephalopathy and Development of Overt Hepatic Encephalopathy

Qiuyu CHENG Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
12:33-12:45 12:33-12:45

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Albumin in Cirrhotic Patients with Ascites

Xinrui WANG The first Hospital of Jilin University
12:45-14:15 12:45-14:15

Mechanism-of-Action for Exosomes Derived from Human Adipose Mesenchymal Stem Cells in Liver Cirrhosis Treatment

Zilong Zhang Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital
13:15-13:30 (UTC+8) 13:15-13:30 Local Time | Satellite Symposium [Satellite Symposium]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:15-13:30 13:15-13:30

New pattern and new challenges, update of optimal strategies for chronic hepatitis B

Zuojiong GONG People's Hospital of Wuhan University
13:30-13:45 (UTC+8) 13:30-13:45 Local Time | Satellite Symposium [Satellite Symposium]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:30-13:45 13:30-13:45

Clinical Cure Advances of Non-Active Hepatitis B's Antigen Carries (IHCs)

Wei GUO Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
13:45-15:15 (UTC+8) 13:45-15:15 Local Time | Concurrent Session 4 - Management of Viral Hepatitis II [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:45-14:05 13:45-14:05

Management of acute and fulminant hepatitis B

Sang Hoon AHN Yonsei University College of Medicine
14:05-14:25 14:05-14:25

A novel, long acting, interferon (Ropeginterferon) for chronic viral hepatitis B or D

Pei-Jer CHEN Hepatitis Research Center, National Taiwan University Hospital
14:25-14:45 14:25-14:45

HBV and MAFLD: intriguing interactions

Wai-Kay SETO The University of Hong Kong
14:45-15:05 14:45-15:05

Extension of treatment criteria in HBV

Harry L.A. JANSSEN University of Toronto and University Health Network
15:05-15:15 15:05-15:15

Panel Discussion

15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
15:30-17:00 (UTC+8) 15:30-17:00 Local Time | State-of-the-art Session 3 [State-of-the-art Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
15:30-16:00 15:30-16:00

Bacterial infections in patients with cirrhosis

Paolo ANGELI University of Padova
16:00-16:30 16:00-16:30

Regulatory innate immune response in hepatitis B infection

Zhenghong YUAN Shanghai Public Health Clinical Center, Fudan University
16:30-17:00 16:30-17:00

New treatment in management of chronic viral hepatitis B

Man-Fung YUEN The University of Hong Kong
17:00-18:30 (UTC+8) 17:00-18:30 Local Time | Concurrent Session 7 - Drug Development for Liver Disease [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:00-17:20 17:00-17:20

HBV Cure Strategy

Patricia MENDEZ / Christophe HEZODE Gilead Science
17:20-17:40 17:20-17:40

Functional cure strategy

Xiaofei CHEN Brii Bioscience
17:40-18:00 17:40-18:00

Distribution and progress of liver diseases

Dandan HUO Chia Tai Tianqin
18:00-18:30 18:00-18:30

Panel Discussion

18:30-18:45 (UTC+8) 18:30-18:45 Local Time | Satellite Symposium [Satellite Symposium]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
18:30-18:45 18:30-18:45

Advantages of DPMAS in the treatment of HBV-ACLF

Tao CHEN Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
18:45-19:00 (UTC+8) 18:45-19:00 Local Time | Satellite Symposium [Satellite Symposium]
Moderator:
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
18:45-19:00 18:45-19:00

Breakthrough、Innovation、Insight

Peng HU The Second Affiliated Hospital of Chongqing Medical University

Meeting Room 2 (UTC+8) 2022-09-17 Local Time

10:00-11:30 (UTC+8) 10:00-11:30 Local Time | Concurrent Session 2 - Management of Ascites and RA [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
10:00-10:20 10:00-10:20

Use and abuse of albumin in management of critically ill patients with cirrhosis

Arun J. SANYAL Virginia Commonwealth University Health System
10:20-10:40 10:20-10:40

Management of refractory ascites

Virendra SINGH Postgraduate Institute of Medical Education and Research, Chandigarh
10:40-11:00 10:40-11:00

Decompensation and recompensation: management of ascites

Hong You Beijing Friendship Hospital, Capital Medical University
11:00-11:20 11:00-11:20

Role of vasoconstrictor in management of refractory ascites and related complications in cirrhosis

Tao HAN School of Medicine, Nankai University
11:20-11:30 11:20-11:30

Panel Discussion

11:30-11:45 (UTC+8) 11:30-11:45 Local Time | Break
11:45-13:15 (UTC+8) 11:45-13:15 Local Time | Oral Presentation 4 [Oral Presentation]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
11:45-11:57 11:45-11:57

Mechanism of MIF promoting inflammatory polarization of liver macrophages mediating acute liver failure

Zezhou WU The First Affiliated Hospital of Guangxi Medical University
11:57-12:09 11:57-12:09

Defection of GLT25D1 Exacerbated Con A Induced Liver Injury by Promoting Polarization of M1-type Macrophage via MAPK Signaling Pathway

Meixin GAO Beijing Ditan Hospital, Capital Medical University
12:09-12:21 12:09-12:21

Observation on short-term effect of sequentially combined multi-modal artificial liver treatment on HBV-related acute-on-chronic liver failure

Xueshi Zhou wuxi NO.5 people's hospital
12:21-12:33 12:21-12:33

G protein-coupled receptor-35 alleviates non-alcoholic steatohepatitis by reprogramming cholesterol homeostasis in hepatocytes

Xiaoli WEI the First Affiliated Hospital of Anhui Medical University,
12:33-12:45 12:33-12:45

Etiology and prognostic criteria of liver failure in southeast China: A multicenter retrospective cohort study between 2018 and 2020

Yan Yan The Fifth People's Hospital of Wuxi
12:45-12:57 12:45-12:57

Enoxaparin attenuates monocrotaline-induced hepatic sinusoidal obstruction syndrome by inhibiting hepatocellular oncostatin M expression

Yuhu Song Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
12:57-13:09 12:57-13:09

FGL2-MCOLN3-autophagy axis-triggered neutrophil extracellular traps exacerbate liver injury in fulminant viral hepatitis

Xitang LI Department and institute of infectious diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
13:45-15:15 (UTC+8) 13:45-15:15 Local Time | Concurrent Session 5 - Bacterial Infections in ESLD [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:45-14:05 13:45-14:05

Algorithm and Choice of Antibiotics in ACLF

Qin NING Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
14:05-14:25 14:05-14:25

Infections in cirrhosis and critical care

Jasmohan BAJAJ Virginia Commonwealth University and McGuire VA Medical Center
14:25-14:45 14:25-14:45

Bacterial infections in ESLD

Salvatore PIANO University Hospital of Padova
14:45-15:05 14:45-15:05

Clinical insight into the involvement of gut and liver to spontaneous bactrial peritonitis in hepatic cirrhosis

Zaigham ABBAS Ziauddin University Hospital
15:05-15:15 15:05-15:15

Panel Discussion

15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
17:00-18:30 (UTC+8) 17:00-18:30 Local Time | Concurrent Session 8 - Diagnosis and Management of Portal Hypertension [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:00-17:20 17:00-17:20

Diagnosis and management of idiopathic noncirrhotic portal hypertension

Jidong Jia Beijing Friendship Hospital Capital Medical University
17:20-17:40 17:20-17:40

Diagnosis and management of portal hypertension

Necati ORMECI Istanbul Health and Technology University
17:40-18:00 17:40-18:00

Chronic Portal vein thrombosis management

Yogesh K. Chawla Postgraduate Institute of Medical Education and Research, Chandigarh
18:00-18:20 18:00-18:20

Hepatitis B virus persistence and reactivation related ACLF

Min Zheng The First Affiliated Hospital of Medical School of Zhejiang University
18:20-18:30 18:20-18:30

Panel Discussion

Meeting Room 3 (UTC+8) 2022-09-17 Local Time

10:00-11:30 (UTC+8) 10:00-11:30 Local Time | Concurrent Session 3 - Hepatic Encephalopathy [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
10:00-10:20 10:00-10:20

Brain complications in critical care in cirrhosis

Jasmohan BAJAJ Virginia Commonwealth University and McGuire VA Medical Center
10:20-10:40 10:20-10:40

A Quick and Early Diagnostic Model for Minimal Hepatic Encephalopathy in ESLD

Tao CHEN Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
10:40-11:00 10:40-11:00

Hepatic encephalopathy: Japanese Guideline 2020 and role of microbiome

Hitoshi YOSHIJI Nara Medical University, Kashihara
11:00-11:20 11:00-11:20

Neurodegeneration in liver disease

Christopher ROSE CRCHUM, Université de Montréal
11:20-11:30 11:20-11:30

Panel Discussion

11:30-11:45 (UTC+8) 11:30-11:45 Local Time | Break
13:45-15:15 (UTC+8) 13:45-15:15 Local Time | Concurrent Session 6 - AKI and HRS [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:45-14:05 13:45-14:05

AKI and HRS

Florence WONG University of Toronto
14:05-14:25 14:05-14:25

Hepatorenal syndrome

W. Ray KIM Stanford University School of Medicine
14:25-14:45 14:25-14:45

Diagnosis and Management of AKI-HRS

Paolo ANGELI University of Padova
14:45-15:05 14:45-15:05

Optimal use of terlipressin in the treatment of hepatorenal syndrome

Arun J. SANYAL Virginia Commonwealth University Health System
15:05-15:15 15:05-15:15

Panel Discussion

15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
17:00-18:30 (UTC+8) 17:00-18:30 Local Time | Concurrent Session 9 - Coagulopathy [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:00-17:20 17:00-17:20

Treating hypo and hyper coagulation the current advances

Ashok CHOUDHURY Institute of Liver and Biliary Sciences
17:20-17:40 17:20-17:40

Hematological issues in liver disease

Tawesak Tanwandee Faculty of Medicine Siriraj Hospital, Mahidol University
17:40-18:00 17:40-18:00

Coagulopathy in severe viral infection

Xiaojing WANG Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
18:00-18:20 18:00-18:20

Management of portal vein thrombosis

Juan Carlos GARCIA-PAGAN University of Barcelona, Barcelona Hepatic Hemodynamic Lab.
18:20-18:30 18:20-18:30

Panel Discussion

2022-09-18 Sun

Meeting Room 1 (UTC+8) 2022-09-18 Local Time

08:30-10:00 (UTC+8) 08:30-10:00 Local Time | State-of-the-art Session 4 [State-of-the-art Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
08:30-09:00 08:30-09:00

Dynamic bioenergetics of sepsis in ACLF

Shiv Kumar Sarin Institute Of Liver And Biliary Sciences
09:00-09:30 09:00-09:30

Mesenchymal Stem Cell Therapy for ACLF and DLC Patients

Fusheng Wang The Fifth Medical Center of PLA General Hospital
09:30-11:00 09:30-11:00

Recent advances and pharmacological treatments in severe alcohol associated hepatitis

Gyongyi SZABO Beth Israel Deaconess Medical Center & Harvard Medical School
10:00-11:30 (UTC+8) 10:00-11:30 Local Time | Concurrent Session 10 - Fatty Liver Disease I [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
10:00-10:20 10:00-10:20

Inflammation in NASH: regulators and therapeutic targets

Bin GAO Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health
10:20-10:40 10:20-10:40

Diagnosis and assessment of cirrhosis in non-alcoholic fatty liver disease

Vincent Wong The Chinese University of Hong Kong
10:40-11:00 10:40-11:00

Leveraging fatty acid oxidation in skeletal muscle for the management of non-alcoholic fatty liver disease

David E. COHEN Weill Cornell Medical Center, New York
11:00-11:20 11:00-11:20

Prevalence and impact of co-existing NAFLD in patients with HBV infection

Chun-Jen LIU Hepatitis Research Center, National Taiwan University Hospital
11:20-11:30 11:20-11:30

Panel Discussion

11:30-11:45 (UTC+8) 11:30-11:45 Local Time | Break
11:45-13:15 (UTC+8) 11:45-13:15 Local Time | Oral Presentation 5 [Oral Presentation]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
11:45-11:57 11:45-11:57

Soluble ST2 Serum Concentration Predicts Efficacy of Artificial liver support system in Acute-on-chronic liver failure.

Rui QIANG Infectious disease hospital affiliated to Suzhou University
11:57-12:09 11:57-12:09

Upregulation of microRNA-125b-5p alleviates acute liver failure through regulating Keap1/Nrf2/HO-1 pathway

Yachao TAO West China Hospital of Sichuan University
12:09-12:21 12:09-12:21

Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus

Daxian Wu the First Affiliated Hospital, Nanchang University
12:21-12:33 12:21-12:33

Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in acute-on-chronic liver failure by inhibiting pyroptosis but not necroptosis signalling

Wang Lu Beijing You An Hospital, Capital Medical University
12:33-12:45 12:33-12:45

Contrast-free ultrasensitive ultrasound imaging for in-vivo quantitative evaluation of hepatic microcirculation in cirrhotic rats

Wei ZHANG The third affiliated hospital of Sun Yat-sen University
12:45-12:57 12:45-12:57

Monocyte subsets predicts outcome of hepatitis B virus related Acute-on-Chronic Liver Failure patients

Hongmin WANG Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital
12:57-13:09 12:57-13:09

Prediction of prognosis of hepatitis B virus-related acute-on-chronic liver failure by LEAP-HBV model based on whole liver volume

Qijuan ZANG First Affiliated Teaching Hospital, School of Medicine (SOM), Xi'an Jiaotong University
13:45-15:15 (UTC+8) 13:45-15:15 Local Time | Concurrent Session 13 - Fatty Liver Disease II [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:45-14:05 13:45-14:05

Viral infection, inflammation and lipid metabolism

Xiaojing WANG Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
14:05-14:25 14:05-14:25

From NAFLD to MAFLD

Jiangao Fan Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
14:25-14:45 14:25-14:45

MAFLD and liver cancer

Jacob George University of Sydney
14:45-15:05 14:45-15:05

MAFLD and extrahepatic manifestation

Lai WEI Beijing Tsinghua Changgung Hospital
15:05-15:15 15:05-15:15

Panel Discussion

15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
15:30-17:00 (UTC+8) 15:30-17:00 Local Time | State-of-the-art Session 5 [State-of-the-art Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
15:30-16:00 15:30-16:00

Biotherapy for liver diseases

Yuquan WEI West China Hospital of Sichuan University
16:00-16:30 16:00-16:30

Optimal management in the era of evolution of the treatment for HCC

Kwang-Hyub HAN Yonsei University College of Medicine
16:30-17:00 16:30-17:00

Ex-vivo Liver Resection and Autotransplantation(ELRA): benign (parasitic) tumors

Jiahong Dong Beijing Tsinghua Chang Gung hospital
17:00-18:30 (UTC+8) 17:00-18:30 Local Time | Concurrent Session 16 - Basic and Clinical Research in Viral Hepatitis [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:00-17:20 17:00-17:20

Evidence to support changing the treatment thresholds in CHB

Patrick T.F. KENNEDY Barts Liver Centre,Blizard Institute,Barts and The London School of Medicine and Dentistry
17:20-17:40 17:20-17:40

Boosting viral-specific immune therapy by mimogen for cure of chronic hepatitis B

Yuzhang WU Army Medical University, Chongqing
17:40-18:00 17:40-18:00

Liver injury in patients with COVID-19

Xinxin ZHANG Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
18:00-18:20 18:00-18:20

Pay more attention to HEV and HBV superinfection clinically

Xiaoguang DOU Shengjing Hospital of China Medical University
18:20-18:30 18:20-18:30

Panel Discussion

18:30-19:00 (UTC+8) 18:30-19:00 Local Time | Wrap-Up

Meeting Room 2 (UTC+8) 2022-09-18 Local Time

10:00-11:30 (UTC+8) 10:00-11:30 Local Time | Concurrent Session 11 - GI Bleeding [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
10:00-10:20 10:00-10:20

Management of cirrhotic complications such as AKI, Variceal hemorrahge

Teerha PIRATVISUTH NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital
10:20-10:40 10:20-10:40

TIPS for the management of acute variceal bleeding

Markus Peck University of Vienna
10:40-11:00 10:40-11:00

High risk varcies screening and surveillance in liver cirrhosis

Jinjun CHEN Nanfang Hospital, Southern Medical University
11:00-11:20 11:00-11:20

Non-invasive and invasive tests of Hepatic Venous Pressure for cirrhotic patients with risk of gastrointestinal bleeding

Mamun AL-MAHTAB Bangabandhu Sheikh Mujib Medical University
11:20-11:30 11:20-11:30

Panel Discussion

11:30-11:45 (UTC+8) 11:30-11:45 Local Time | Break
11:45-13:15 (UTC+8) 11:45-13:15 Local Time | Oral Presentation 6 [Oral Presentation]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
11:45-11:57 11:45-11:57

A novel prognostic nomogram for older patients with acute-on-chronic liver diseases (AoCLD): a nationwide, multicenter, prospective cohort study

Ju ZOU Xiangya Hospital, Central South University
11:57-12:09 11:57-12:09

Establishment and validation of a quick bedside test with number connection test A and animal and vegetable naming test for minimal hepatic encephalopathy

Qiuyu CHENG Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
12:09-12:21 12:09-12:21

Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NFκB pathways

Mengxia Zhang Tianjin Medical University, School of Basic Medical Sciences
12:21-12:33 12:21-12:33

Single-Cell Profiling Reveals the Metastasis-Associated Immune Signature of Hepatocellular Carcinoma

Jin Shang Sichuan Provincial People's Hospital
12:33-12:45 12:33-12:45

microRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression

Yong HE Shanghai Institute of Materia Medica, Chinese Academy of Sciences
12:45-12:57 12:45-12:57

A Chinese system of staging and treatment strategy for post-hepatectomy recurrent hepatocellular carcinoma

Jing LI Eastern Hepatobiliary Surgery Hospital
12:57-13:09 12:57-13:09

Presence of liver inflammation and fibrosis in Asian patients with chronic hepatitis B in the grey zone

Jian Wang Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University
13:45-15:15 (UTC+8) 13:45-15:15 Local Time | Concurrent Session 14 - Basic Research in Liver Disease [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:45-14:05 13:45-14:05

HBV capsid assembly modulators in the functional cure of CHB

Ju-Tao GUO Baruch S. Blumberg Institute
14:05-14:25 14:05-14:25

HBV cure: immunological mechanisms

Robert THIMME Department of Medicine II, Medical Center – University of Freiburg
14:25-14:45 14:25-14:45

Hyperdynamic circulation in cirrhosis

Hongqun LIU Cumming School of Medicine, Universuity of Calgary
14:45-15:05 14:45-15:05

Revisit the natural history of chronic HBV infection

Fengmin LU School of basic medicine Peking University
15:05-15:15 15:05-15:15

Panel Discussion

15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
17:00-18:30 (UTC+8) 17:00-18:30 Local Time | Concurrent Session 17- ALD, Autoimmune, DILI and Liver Injury in ESLD [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:00-17:20 17:00-17:20

Hypoxic hepatitis update

Samuel S. LEE University of Calgary Cumming School of Medicine
17:20-17:40 17:20-17:40

The pathogenesis of primary biliary cholangitis

Xiong MA Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
17:40-18:00 17:40-18:00

Acute presentation of AIH - how to find and manage

Atsushi TANAKA Teikyo University School of Medicine
18:00-18:20 18:00-18:20

Multi-organ injury in the metabolic syndrome

David A. BRENNER University of California San Diego
18:20-18:30 18:20-18:30

Panel Discussion

Meeting Room 3 (UTC+8) 2022-09-18 Local Time

10:00-11:30 (UTC+8) 10:00-11:30 Local Time | Concurrent Session 12 - Management of ACLF [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
10:00-10:20 10:00-10:20

Acute HBV related liver failure

Raymond T. CHUNG Massachusetts General Hospital, Boston
10:20-10:40 10:20-10:40

Role of nutrition in critical care

Diana A. Payawal Fatima University Medical Center, Manila
10:40-11:00 10:40-11:00

Diagnosis and treatment of end-stage liver disease combined with severe infection

Tao CHEN Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
11:00-11:20 11:00-11:20

Management of ACLF in the context of liver transplantation

Didier SAMUEL Hospital Paul Brousse, APHP, Centre Hepato Biliaire
11:20-11:30 11:20-11:30

Panel Discussion

11:30-11:45 (UTC+8) 11:30-11:45 Local Time | Break
13:45-15:15 (UTC+8) 13:45-15:15 Local Time | Concurrent Session 15 - Sepsis and Liver Support [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
13:45-14:05 13:45-14:05

Algorithms for managing MDR infections in liver ICU

Rakhi Maiwall Institute Of Liver And Biliary Sciences
14:05-14:25 14:05-14:25

Mesenchymal stem cells therapies for Covid-19: from bench to bedside

Bingliang LIN The Third Affiliated Hospital of Sun Yat-sen University
14:25-14:45 14:25-14:45

Progress in diagnosis and treatment of sepsis-related cholestatic liver disease

Ke MA Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
14:45-15:05 14:45-15:05

ACLF and organ support

Yu CHEN Beijing Youan Hospital, Capital Medical University
15:05-15:15 15:05-15:15

Panel Discussion

15:15-15:30 (UTC+8) 15:15-15:30 Local Time | Break
17:00-18:30 (UTC+8) 17:00-18:30 Local Time | Concurrent Session 18 - HCC and Transplant [Concurrent Session]
Beijing Time (UTC+8) Local Time Talk Title Speaker Affiliation
17:00-17:20 17:00-17:20

HCC: Who to transplant?

Saeed S. HAMID Aga Khan University,Karachi
17:20-17:40 17:20-17:40

Biliary complications due to living donor liver transplantation

A. Kadir DOKMECI Liver Transplantation Center, Ankara University
17:40-18:00 17:40-18:00

HCC risk and surveillance in patients with cirrhosis

Mindie H. NGUYEN Stanford University Medical Center
18:00-18:20 18:00-18:20

Prevention of HBV-related HCC through antiviral treatment

Jinlin HOU Nanfang Hospital, Southern Medical University
18:20-18:30 18:20-18:30

Panel Discussion